Ms. Saadia Nisar Profile

Saadia Nisar

SPIE Involvement:

Author

Publications (1)

This will count as one of your downloads.

You will have access to both the presentation and article (if available).

DOWNLOAD NOW

This content is available for download via your institution's subscription. To access this item, please sign in to your personal account.

Email or Username Forgot your username?

Password Forgot your password?

Show

Keep me signed in

No SPIE account? Create an account

Proceedings Article | 5 March 2021 Presentation + Paper

Developing a novel biodegradable nanodrug platform for overcoming the challenges in treating pancreatic ductal adenocarcinoma (PDAC)

Saadia Nisar, Shannon Handley, Sandhya Clement

Proceedings Volume 11659, 1165906 (2021) https://doi.org/10.1117/12.2578964

KEYWORDS: Nanoparticles, Cell death, X-rays, Spectroscopy, Receptors, Cancer, Absorption spectroscopy, Absorbance

Read Abstract +

Pancreatic ductal adenocarcinoma (PDAC) is a deep seated and aggressive tumour which resists most current therapeutics resulting in only 5% survival rate. Gemcitabine, although the first line of treatment still has limited therapeutic value due to severe side effects. New treatment modalities are urgently required which efficiently deliver drugs to the target tumour area without causing adverse off-target side effects. We aimed to combine two clinical treatments for cancer, chemotherapy and RadioDynamic Therapy (RDT), to overcome current treatment for PDAC. In this project, specially designed nanoparticles (NP) were utilised as nanodrug carriers. Our poly(lactic-co-glycolide) (PLGA) nanoparticles were successfully loaded with both chemotherapeutic agent Gemcitabine and RDT agent Verteporfin. Addition surface conjugation with GE11 peptide allowed to precisely target Panc-1 cancer cell lines overexpressing EGFR receptors. Our results show PLGA was successfully fine-tuned with desirable physicochemical properties. Gemcitabine and Verteporfin were sufficiently loaded into the PLGA NP and surface conjugation with GE11 peptide was confirmed using absorbance spectroscopy. The resulting GE11-PLGA-VP-GEM NPs showed size 86.38±15 nm, polydispersity 0.57±0.1 and zeta potential measurements of -2.87±1 mV. Encapsulation efficiency (EE) was determined to be 20% for Verteporfin and 24% for Gemcitabine. This combination offers a multimodal treatment system whereby Gemcitabine is able to be effectively delivered to Panc-1 cells and, simultaneously, Verteporfin, induced by Xray radiation generates ROS to cause cell death. Cellular uptake studies were evaluated and the treatment of live Panc-1 cells with GE11-PLGA-VP-GEM NP induced cell death. Furthermore, Verteporfin, excited at clinically relevant X-ray dosages generated ROS.

My Library

You currently do not have any folders to save your paper to! Create a new folder below.

Folder Name

Folder Description

View contact details

UPDATE YOUR PROFILE

Is this your profile? Update it now.

Sign into your SPIE.org account

Don’t have a profile and want one?

Create an account on SPIE.org

Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks. You are receiving this notice because your organization may not have SPIE eBooks access.*

*Shibboleth/Open Athens users─please sign in to access your institution's subscriptions.

To obtain this item, you may purchase the complete book in print or electronic format on SPIE.org.

ORGANIZATIONAL
Sign in with credentials provided by your organization.

Organizational Username

Organizational Password

Show/Hide Password

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members:

Non-members: ADD TO CART

Keywords/Phrases

Search In:

Publication Years